399 related articles for article (PubMed ID: 26292932)
1. [Histiocytic diseases in childhood and adolescence].
Vokuhl C; Oschlies I; Klapper W; Leuschner I
Pathologe; 2015 Sep; 36(5):443-50. PubMed ID: 26292932
[TBL] [Abstract][Full Text] [Related]
2. The histiocytoses of childhood.
Malone M
Histopathology; 1991 Aug; 19(2):105-19. PubMed ID: 1757066
[TBL] [Abstract][Full Text] [Related]
3. [Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group].
Adam Z; Szturz P; Pour L; Krejčí M; Zahradová L; Tomíška M; Král Z; Koukalová R; Rehák Z; Mayer J
Vnitr Lek; 2012 Jun; 58(6):455-65. PubMed ID: 22913238
[TBL] [Abstract][Full Text] [Related]
4. Histiocytic disorders of the gastrointestinal tract.
Detlefsen S; Fagerberg CR; Ousager LB; Lindebjerg J; Marcussen N; Nathan T; Sørensen FB
Hum Pathol; 2013 May; 44(5):683-96. PubMed ID: 23063502
[TBL] [Abstract][Full Text] [Related]
5. [Histiocytoses: General classification and molecular criteria].
Emile JF; Charlotte F; Chassagne-Clement C; Copin MC; Fraitag S; Mokhtari K; Moreau A
Presse Med; 2017 Jan; 46(1):46-54. PubMed ID: 26952138
[TBL] [Abstract][Full Text] [Related]
6. Non-Langerhans cell histiocytosis with isolated CNS involvement: an unusual variant of Erdheim-Chester disease.
Conley A; Manjila S; Guan H; Guthikonda M; Kupsky WJ; Mittal S
Neuropathology; 2010 Dec; 30(6):634-47. PubMed ID: 20337948
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
Geerlinks AV; Abla O
Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
[TBL] [Abstract][Full Text] [Related]
8. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
[TBL] [Abstract][Full Text] [Related]
9. [Erdheim-Chester disease and Rosai-Dorfman disease: Pathological, radiological and clinical features of adult non-Langerhans cell histiocytosis].
Bösmüller H; Nann D; Horger M; Fend F
Pathologe; 2015 Sep; 36(5):458-66. PubMed ID: 26305142
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
[TBL] [Abstract][Full Text] [Related]
11. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.
Bonometti A; Ferrario G; Parafioriti A; Giardino D; Simonetti F; Ginori A; Passoni E; Berti E;
J Cutan Pathol; 2021 May; 48(5):637-643. PubMed ID: 33188581
[TBL] [Abstract][Full Text] [Related]
12. PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours.
Ungureanu IA; Cohen-Aubart F; Héritier S; Haroche J; Donadieu J; Emile JF
Histopathology; 2023 Aug; 83(2):320-325. PubMed ID: 37012662
[TBL] [Abstract][Full Text] [Related]
13. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
[TBL] [Abstract][Full Text] [Related]
14. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
Haroche J; Abla O
Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
[TBL] [Abstract][Full Text] [Related]
15. Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses.
Mavrogenis AF; Igoumenou VG; Antoniadou T; Megaloikonomos PD; Agrogiannis G; Foukas P; Papageorgiou SG
EFORT Open Rev; 2018 Jun; 3(6):381-390. PubMed ID: 30034819
[TBL] [Abstract][Full Text] [Related]
16. OCT2 expression in histiocytoses.
Ungureanu IA; Cohen-Aubart F; Héritier S; Fraitag S; Charlotte F; Lequain H; Hélias-Rodzewicz Z; Haroche J; Donadieu J; Emile JF
Virchows Arch; 2023 Jul; 483(1):81-86. PubMed ID: 36754897
[TBL] [Abstract][Full Text] [Related]
17. Descriptive Analysis of Histiocytic and Dendritic Cell Neoplasms: A Single-Institution Experience.
Kim HM; Yang WI; Lyu CJ; Hahn SM; Yoon SO
Yonsei Med J; 2020 Sep; 61(9):774-779. PubMed ID: 32882761
[TBL] [Abstract][Full Text] [Related]
18. Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases.
Berres ML; Allen CE; Merad M
Adv Immunol; 2013; 120():127-61. PubMed ID: 24070383
[TBL] [Abstract][Full Text] [Related]
19. The cutaneous "histiocytoses".
Zelger B; Burgdorf WH
Adv Dermatol; 2001; 17():77-114. PubMed ID: 11758126
[No Abstract] [Full Text] [Related]
20. CNS Erdheim-Chester Disease: A Challenge to Diagnose.
Pan Z; Kleinschmidt-DeMasters BK
J Neuropathol Exp Neurol; 2017 Dec; 76(12):986-996. PubMed ID: 29096034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
